comprehensive -WSS

comprehensive

author：leisure time 2025-10-01 11:43:53 - browse：4374

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： PhRMA sues HHS over Medicare drug price negotiation

focus

WSS

Roche to buy Carmot Therapeutics, developer of obesity drugs

Connecting traumatic brain injury and domestic violence

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

Community addresses injustice for Long Island mothers

Community addresses injustice for Long Island mothers

Chemotherapy shortages won’t get better under Biden’s latest plan

focus

comprehensive

focus

Tori Bowie and the unacceptable rates of Black maternal death

Brain 'hot spot' may explain why African Americans feel greater pain

Hepatitis C has a cure — but many Americans still lack access to it

In diabetes hearing, Sanders takes on a new foe: food makers

Jerome Adams on the need for new antivirals for Covid

Teach medical students about patients with intellectual disabilities

Guidelines to prevent youth baseball injuries need more muscle

AI models in health care face new federal disclosure requirements

Trump demands the U.S. pay no more for drugs than other countries … again

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

leisure time

Meta looks to target Twitter with a rival app called Threads

Grail is spending more than ever lobbying Congress

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

A new study asks: Are we harming blood donors by taking blood?

A new study asks: Are we harming blood donors by taking blood?

A new study asks: Are we harming blood donors by taking blood?

focus

focus

hotspot

leisure time